抗 TNFa 生物类似药的皮肤自身免疫现象。基于案例的综述。
Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review.
机构信息
Department of Internal Medicine, Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece.
Department of Pathology, Medical School, University of Ioannina, Ioannina, Greece.
出版信息
Curr Rheumatol Rev. 2021;17(2):267-270. doi: 10.2174/1573397116666201119151349.
BACKGROUND
Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.
CASE PRESENTATION
A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide and prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg/week subcutaneously. He responded well to the treatment, but a year later, he developed erythematous skin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible with Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical steroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment.
CONCLUSION
Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and other anti-TNFα biosimilars. Rheumatologists dealing with patients on anti-TNFα biosimilars should be aware of and recognize these complications.
背景
银屑病（Pso）是一种常见的慢性炎症性疾病，影响皮肤，男女均可患病，且各年龄段均可发病。它可能与其他慢性炎症性肌肉骨骼疾病和某些药物有关，包括肿瘤坏死因子α（TNFα）拮抗剂。
病例介绍
一名 64 岁男性，患有血清阴性类风湿关节炎（RA），对来氟米特和泼尼松耐药，接受 SB-4（Benepali）治疗，即一种每周皮下注射 50mg 的依那西普生物类似药。他对治疗反应良好，但一年后，他出现了主要影响双手手掌的红斑性皮肤疹。皮肤活检显示与银屑病一致的图像。停用 SB-4 后，加用局部类固醇治疗，皮肤病变消失。这是唯一一例与 SB-4 治疗相关的银屑病皮肤病变的病例。
结论
因此，我们复习并讨论了与 SB-4 和其他抗 TNFα 生物类似药相关的 Pso 病例的相关文献。处理接受抗 TNFα 生物类似药治疗的患者的风湿病学家应了解并认识到这些并发症。
Zotero 插件